Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: We sought to evaluate the efficacy of intravenous dexamethasone in reducing rebound pain post-orthopedic wrist and hand surgery, administered prior to supraclavicular brachial plexus blockade.
Methods: We conducted a randomized placebo-controlled trial on 56 patients scheduled for elective wrist and hand surgery under supraclavicular brachial plexus blockade. We randomized participants into either a control group, receiving 0.9% of intravenous saline, or a dexamethasone group, receiving 0.11 mg·kg of intravenous dexamethasone. The primary outcome was the difference in pain scores before vs after block resolution. Secondary outcomes included the incidence of rebound pain, pain scores, cumulative opioid consumption, patient satisfaction with postoperative analgesia, and block-related complications in the first 24 hr postoperatively.
Results: The mean (standard deviation [SD]) pain score difference was significantly larger in the control group (7.3 [1.9]) compared with the dexamethasone group (4.7 [2.1]), with a mean difference between groups of 2.6 (95% confidence interval, 1.5 to 3.7; P < 0.001). The incidence of rebound pain was also significantly higher in the control group (79% vs 32%; P < 0.001). The cumulative opioid consumption in 24 hr was greater in the control group than in the dexamethasone group (median [interquartile range (IQR)], 72 [54-97] mg vs 25 [14-60] mg; P < 0.001). We found no significant differences in postoperative complications.
Conclusions: Preoperative administration of 0.11 mg·kg intravenous dexamethasone significantly reduced rebound pain within 24 hr after wrist and hand surgery under supraclavicular brachial plexus blockade. The results of our trial support the use of intravenous dexamethasone as an effective method for managing postoperative pain for wrist and hand surgery under supraclavicular brachial plexus blockade.
Study Registration: www.CRIS.nih.go.kr ( KCT0007208 ); first submitted 5 April 2022.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12630-025-02992-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Seeking a Viable Alternative: A Prospective, Randomized, Controlled, Double-Blind Non-Inferiority Study of Oral Versus IV Dexamethasone in Children Undergoing Tonsillectomy.
Paediatr Anaesth
September 2025
Department of Otorhinolaryngology, Section of Pediatric Otorhinolaryngology, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.
Introduction: Tonsillectomy is associated with a high rate of postoperative nausea and vomiting (PONV), ranging between 40% and 73%, and dexamethasone has been found to have a prophylactic effect on PONV in children undergoing tonsillectomy. In 2020, there was a sudden, severe shortage of intravenous dexamethasone given its role in treating patients with COVID-19. The primary aim of this study was to investigate the viability of an alternative: non-inferiority of oral versus intravenous dexamethasone for preventing PONV.
View Article and Find Full Text PDFA relapse of acute group B streptococcus meningitis in a healthy adult: Case report and review of the literatures.
J Gen Fam Med
September 2025
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital Mahidol University Samut Prakan Thailand.
(GBS) is a rare cause of meningitis in healthy adults. We report the case of a healthy 33-year-old man with acute GBS meningitis who experienced relapsed high-grade fever and increased intracranial pressure following completing intravenous antibiotics. A short course of corticosteroids, along with additional antibiotics, improved the cerebrospinal fluid (CSF) profile, and no further complications occurred after the recurrent episodes.
View Article and Find Full Text PDFPresumed Cerebral Vasculitis Following Pneumococcal Meningitis: A Rare but Life-Threatening Complication.
Case Rep Med
August 2025
Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
A 65-year-old woman presented with pneumococcal sepsis and meningitis. Despite appropriate antimicrobial therapy and intravenous (IV) dexamethasone, her mental status did not improve. Findings of brain imaging were suggestive of cerebral vasculitis.
View Article and Find Full Text PDFPharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trial.
BMC Med
August 2025
Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Background: This phase I trial aimed to assess the pharmacokinetics (PK), safety, and preliminary efficacy of a single dose of HR20013 (mixed formulation of fosrolapitant and palonosetron) plus dexamethasone in patients with malignant solid tumors.
Methods: Solid tumor patients who were naive to cisplatin-based chemotherapy and scheduled to receive the single-day cisplatin-based chemotherapy were enrolled. Patients would receive a single intravenous infusion of HR20013 (Day 1) before cisplatin-based chemotherapy, alongside oral dexamethasone (Day 1, 12 mg, once a day; Day 2-4, 3.
Acute Hemolytic Anemia and Immune Thrombocytopenia: A Rare Case of Parvovirus B19-Induced Evans Syndrome.
Cureus
July 2025
Internal Medicine, AdventHealth Orlando, Orlando, USA.
Evans syndrome is a rare condition that can be seen among patients with pre-existing rheumatological disorders such as lupus, rheumatoid arthritis, or adult-onset Still's disease. There is an association between positive anti-phospholipid antibodies and the development of Evans syndrome, but the underlying pathophysiology remains unknown. To our knowledge, this is one of the few case reports to date that describes the development of Evans syndrome triggered by parvovirus B19 in patients with pre-existing positive antiphospholipid antibodies.
View Article and Find Full Text PDF